Research Leadership Council
Nuclear Control of Cell Growth and Differentiation
Cell Response and Regulation
Experimental Therapeutics
Cancer Control and Population Sciences
Cancer Center members contribute to the mission of the Center via their participation in research, including laboratory, clinical, and population-based efforts.
Huntsman Cancer Institute (HCI) has four cancer research programs:
The four programs drive progress at our National Cancer Institute-designated Comprehensive Cancer Center by:
HCI Cancer Center members enjoy a variety of benefits, including eligibility for leadership roles in the Center, institutional funding opportunities, and scientific/administrative support.
The Research Leadership Council (RLC) has responsibility for coordination, planning, and oversight of HCI's research portfolio and is accountable for the design and execution of Cancer Center goals. The Council is chaired by the Director and includes representatives from the Director's Cabinet, all Cancer Program Leaders, Staff Investigators, HCI-managed Shared Resource Directors, representation of HCI clinical research operations, and senior administrators. This group participates actively in strategic planning for HCI research initiatives, and directs evaluation of Programs, Shared Resources, and membership.
View the Research Leadership Council Membership
Martin McMahon, PhD, and his research group study the genetic mutations that contribute to lung cancer. About 30% of lung cancers can now be treated based on the disease’s specific genetics. McMahon is hopeful that each subset of lung cancer will soon have its own precision treatment.... Read More
Researchers at Huntsman Cancer Institute at the University of Utah discovered in laboratory studies that an experimental drug called selinexor may block a crucial survival pathway exploited by myelofibrosis cells.... Read More
A personalized prognosis for patients diagnosed with triple-negative breast cancer was the goal of a new study by Katherine Varley, PhD, researcher at Huntsman Cancer Institute (HCI) and assistant professor of oncological sciences at the University of Utah. ... Read More
Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN, which evaluated the effectiveness and safety of a new drug, apalutamide, to treat advanced prostate cancers. ... Read More
Bryan Welm, PhD, has found a unique way to merge his love for science and art. ... Read More
In the largest study of its kind, more than half of patients with advanced prostate cancers appear to be strong candidates for targeted cancer therapies... Read More
